ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
An Emerging Target for Solid Tumors -- CD73 Development in China
June 16, 2021CD73, also known as Ecto-5′-Nucleotidase, is a cell surface enzyme, which is widely expressed on the surface of endothelial cells of human bodies, lymphocytes such as Treg and other cells. -
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
February 07, 2021I-Mab announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. -
Researchers identify immune-suppressing target in glioblastoma
December 24, 2019Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with ...
Pharma Sources Insight January 2025
